Algeta’s Partner Bayer Submits Radium-223 for EU Marketing Authorization

News   Apr 22, 2013

 
Algeta’s Partner Bayer Submits Radium-223 for EU Marketing Authorization
 
 
 

RELATED ARTICLES

Targeted Cancer Treatment Could be Possible Thanks to Insights into Cells’ Energy Supply

News

Researchers have shown that the enzyme EXD2 is critically involved in maintaining efficient protein production in mitochondria - the compartment responsible for making the energy required for cells to survive and replicate.


It is hoped the discovery could be used to target tumours in cancer patients in a new way while also significantly adding to the understanding of the vital role mitochondria plays in the functioning of a healthy cell.

READ MORE

Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”

News

The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.

READ MORE

3D Structure of DHHC Proteins Provides Blueprint for Drug Design

News

The first three-dimensional structure of DHHC proteins — enzymes involved in many cellular processes, including cancer — explains how they function and may offer a blueprint for designing therapeutic drugs.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE